Cognitive function in metformin exposed children, born to mothers with PCOS - follow-up of an RCT

Hanne Klæboe Greger, Liv Guro Engen Hanem, Heidi Furre Østgård, Eszter Vanky, Hanne Klæboe Greger, Liv Guro Engen Hanem, Heidi Furre Østgård, Eszter Vanky

Abstract

Background: Metformin is widely used in pregnancy to treat gestational diabetes mellitus and polycystic ovary syndrome (PCOS). Association between PCOS and developmental delay in offspring, and larger head circumference of metformin-exposed newborns has been reported. The objective of this study was to explore whether metformin exposure in utero had any effect on offspring cognitive function.

Method: The current study is a follow-up of two randomized, placebo-controlled studies which were conducted at 11 public hospitals in Norway In the baseline studies (conducted in 2000-2003, and 2005-2009), participants were randomized to metformin 1700 and 2000 mg/d or placebo from first trimester to delivery. There was no intervention in the current study. We invited parents of 292 children to give permission for their children to participate; 93 children were included (mean age 7.7 years). The follow-up study was conducted in 2014-2016. The Wechsler Preschool and Primary Scale of Intelligence version III and the Wechsler Intelligence Scale for Children version IV were applied for cognitive assessment. Androstenedione and testosterone were measured in maternal blood samples at four time-points in pregnancy.

Results: We found no difference in mean, full scale IQ in metformin (100.0 (SD 13.2)) vs. placebo-exposed (100.9 (SD 10.1)) children. There was an association between metformin exposure in utero and borderline intellectual function of children (full scale IQ between 70 and 85). Free testosterone index in gestational week 19, and androstenedione in gestational week 36 correlated positively to full scale IQ.

Conclusions: We found no evidence of long-term effect of metformin on average child cognitive function. The increase of borderline intellectual functioning in metformin-exposed children must be interpreted with caution due to small sample size.

Trial registration: The baseline study was registered on 12 September 2005 at the US National Institute of Health (ClinicalTrials.gov) # NCT00159536.

Keywords: Androgen; Metformin; Offspring cognitive function; PCOS.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow-chart of inclusion and randomization to either metformin or placebo in the baseline studies (PregMet study and Pilot study), and the present study (Cogmet study)

References

    1. Vanky E, Zahlsen K, Spigset O, Carlsen SM. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril. 2005;83(5):1575–1578. doi: 10.1016/j.fertnstert.2004.11.051.
    1. Given JE, Loane M, Garne E, Addor MC, Bakker M, Bertaut-Nativel B, Gatt M, Klungsoyr K, Lelong N, Morgan M, et al. Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study. BMJ. 2018;361:k2477. doi: 10.1136/bmj.k2477.
    1. Lawrence JM, Andrade SE, Avalos LA, Beaton SJ, Chiu VY, Davis RL, Dublin S, Pawloski PA, Raebel MA, Smith DH, et al. Prevalence, trends, and patterns of use of antidiabetic medications among pregnant women, 2001-2007. Obstet Gynecol. 2013;121(1):106–114. doi: 10.1097/AOG.0b013e318278ce86.
    1. Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28–38.e25. doi: 10.1016/j.fertnstert.2011.09.024.
    1. Roos N, Kieler H, Sahlin L, Ekman-Ordeberg G, Falconer H, Stephansson O. Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study. BMJ. 2011;343:d6309. doi: 10.1136/bmj.d6309.
    1. Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12(6):673–683. doi: 10.1093/humupd/dml036.
    1. Boomsma CM, Fauser BC, Macklon NS. Pregnancy complications in women with polycystic ovary syndrome. Semin Reprod Med. 2008;26(1):72–84. doi: 10.1055/s-2007-992927.
    1. Palomba S, de Wilde MA, Falbo A, Koster MP, La Sala GB, Fauser BC. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015;21(5):575–592. doi: 10.1093/humupd/dmv029.
    1. Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol. 2011;204(6):558.e551–558.e556. doi: 10.1016/j.ajog.2011.03.021.
    1. Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod. 2004;19(8):1734–1740. doi: 10.1093/humrep/deh347.
    1. Vanky E, Stridsklev S, Heimstad R, Romundstad P, Skogoy K, Kleggetveit O, Hjelle S, von Brandis P, Eikeland T, Flo K, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010;95(12):E448–E455. doi: 10.1210/jc.2010-0853.
    1. Løvvik Tone S, Carlsen Sven M, Salvesen Øyvind, Steffensen Berglind, Bixo Marie, Gómez-Real Francisco, Lønnebotn Marianne, Hestvold Kristin V, Zabielska Renata, Hirschberg Angelica L, Trouva Anastasia, Thorarinsdottir Solveig, Hjelle Sissel, Berg Ann Hilde, Andræ Frida, Poromaa Inger S, Mohlin Johanna, Underdal Maria, Vanky Eszter. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology. 2019;7(4):256–266. doi: 10.1016/S2213-8587(19)30002-6.
    1. Hjorth-Hansen A, Salvesen O, Engen Hanem LG, Eggebo T, Salvesen KA, Vanky E, Odegard R. Fetal growth and birth anthropometrics in metformin-exposed offspring born to mothers with PCOS. J Clin Endocrinol Metab. 2018;103(2):740–747. doi: 10.1210/jc.2017-01191.
    1. Hanem LGE, Stridsklev S, Juliusson PB, Salvesen O, Roelants M, Carlsen SM, Odegard R, Vanky E. Metformin use in PCOS pregnancies increases the risk of offspring overweight at 4 years of age: follow-up of two RCTs. J Clin Endocrinol Metab. 2018;103(4):1612–1621. doi: 10.1210/jc.2017-02419.
    1. Hanem LGE, Salvesen O, Juliusson PB, Carlsen SM, Nossum MCF, Vaage MO, Odegard R, Vanky E. Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial. Lancet Child Adolesc Health. 2019;3(3):166–174. doi: 10.1016/S2352-4642(18)30385-7.
    1. Bell GA, Sundaram R, Mumford SL, Park H, Mills J, Bell EM, Broadney M, Yeung EH. Maternal polycystic ovarian syndrome and early offspring development. Hum Reprod. 2018;33(7):1307–1315. doi: 10.1093/humrep/dey087.
    1. Kosidou K, Dalman C, Widman L, Arver S, Lee BK, Magnusson C, Gardner RM. Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in Sweden. Mol Psychiatry. 2016;21(10):1441–1448. doi: 10.1038/mp.2015.183.
    1. Kosidou K, Dalman C, Widman L, Arver S, Lee BK, Magnusson C, Gardner RM. Maternal polycystic ovary syndrome and risk for attention-deficit/hyperactivity disorder in the offspring. Biol Psychiatry. 2017;82(9):651–659. doi: 10.1016/j.biopsych.2016.09.022.
    1. Ijas H, Vaarasmaki M, Saarela T, Keravuo R, Raudaskoski T. A follow-up of a randomised study of metformin and insulin in gestational diabetes mellitus: growth and development of the children at the age of 18 months. BJOG. 2015;122(7):994–1000. doi: 10.1111/1471-0528.12964.
    1. Tertti K, Eskola E, Ronnemaa T, Haataja L. Neurodevelopment of two-year-old children exposed to metformin and insulin in gestational diabetes mellitus. J Dev Behav Pediatr. 2015;36(9):752–757. doi: 10.1097/DBP.0000000000000230.
    1. Wouldes TA, Battin M, Coat S, Rush EC, Hague WM, Rowan JA. Neurodevelopmental outcome at 2 years in offspring of women randomised to metformin or insulin treatment for gestational diabetes. Arch Dis Child Fetal Neonatal Ed. 2016.
    1. Revised 2003 Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod2004, 19(1):41–47.
    1. Diagnostic and statistical manual of mental disorders, 5th edn. Washington DC: American Psychiatric Association; 2013.
    1. Schalock RL, Borthwick-Duffy SA, Bradley VJ, Buntinx WHE, Coulter DL, Craig EM, Gomez SC, Lachapelle Y, Luckasson R, Reeve A, Shogren KA, Snell ME, Spreat S, Tassé MJ, Thompson JR, Verdugo-Alonso MA, Wehmeyer ML, Yeager MH. Intellectual disability: definition, classification, and Systems of Supports. 11. Washington, DC: American Association of Intellectual and Developmental Disabilities; 2010.
    1. Strauss E, Sherman EMS, Spreen O. A compendium of neuropsychological tests: administration, norms, and commentary. 3. New York: Oxford University Press; 2006.
    1. Vanky E, Carlsen SM. Androgens and antimullerian hormone in mothers with polycystic ovary syndrome and their newborns. Fertil Steril. 2012;97(2):509–515. doi: 10.1016/j.fertnstert.2011.11.021.
    1. Niklasson A, Albertsson-Wikland K. Continuous growth reference from 24th week of gestation to 24 months by gender. BMC Pediatr. 2008;8:8. doi: 10.1186/1471-2431-8-8.
    1. Juliusson PB, Roelants M, Nordal E, Furevik L, Eide GE, Moster D, Hauspie R, Bjerknes R. Growth references for 0-19 year-old Norwegian children for length/height, weight, body mass index and head circumference. Ann Hum Biol. 2013;40(3):220–227. doi: 10.3109/03014460.2012.759276.
    1. Smithers LG, Lynch JW, Yang S, Dahhou M, Kramer MS. Impact of neonatal growth on IQ and behavior at early school age. Pediatrics. 2013;132(1):e53–e60. doi: 10.1542/peds.2012-3497.
    1. Gale CR, O'Callaghan FJ, Bredow M, Martyn CN. The influence of head growth in fetal life, infancy, and childhood on intelligence at the ages of 4 and 8 years. Pediatrics. 2006;118(4):1486–1492. doi: 10.1542/peds.2005-2629.
    1. Bonnet-Brilhault F, Rajerison TA, Paillet C, Guimard-Brunault M, Saby A, Ponson L, Tripi G, Malvy J, Roux S. Autism is a prenatal disorder: evidence from late gestation brain overgrowth. Autism Res. 2018;11(12):1635–1642. doi: 10.1002/aur.2036.
    1. Carr A, O'Reilly G. The handbook of intellectual disability and clinical psychology practice. 2. New York: Routledge; 2016. Diagnosis, classification and epidemiology; pp. 3–44.
    1. Nisbett RE, Aronson J, Blair C, Dickens W, Flynn J, Halpern DF, Turkheimer E. Intelligence: new findings and theoretical developments. Am Psychol. 2012;67(2):130–159. doi: 10.1037/a0026699.
    1. Neisser U, Boodoo G, Bouchard TJ, Jr, Boykin AW, Brody N, Ceci SJ, Halpern DF, Loehlin JC, Perloff R, Sternberg RJ, et al. Intelligence: Knowns and unknowns. Am Psychol. 1996;51(2):77–101. doi: 10.1037/0003-066X.51.2.77.
    1. Szumski G, Firkowska-Mankiewicz A, Lebuda I, Karwowski M. Predictors of success and quality of life in people with borderline intelligence: the special school label, personal and social resources. J Appl Res Intellect Disabil. 2018;31(6):1021–1031. doi: 10.1111/jar.12458.
    1. Deary IJ, Yang J, Davies G, Harris SE, Tenesa A, Liewald D, Luciano M, Lopez LM, Gow AJ, Corley J, et al. Genetic contributions to stability and change in intelligence from childhood to old age. Nature. 2012;482(7384):212–215. doi: 10.1038/nature10781.
    1. Flensborg-Madsen Trine, Mortensen Erik Lykke. Birth Weight and Intelligence in Young Adulthood and Midlife. Pediatrics. 2017;139(6):e20163161. doi: 10.1542/peds.2016-3161.
    1. Leech T, Chattipakorn N, Chattipakorn SC. The beneficial roles of metformin on the brain with cerebral ischaemia/reperfusion injury. Pharmacol Res. 2019;146:104261. doi: 10.1016/j.phrs.2019.104261.
    1. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012;122(6):253–270. doi: 10.1042/CS20110386.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다